Assurant news

Record Q2 results with 24% EBITDA growth and 26% EPS increase; raised 2026 outlook; expected 8% annual sales growth and 13% EPS growth

Global risk management solutions provider with 8.5% expected sales growth in 2026 and Zacks Rank #2 rating. Positioned well in housing and lifestyle markets with strong brand partnerships.

Strong 32.9% one-year performance, raised 2026 guidance for Global Lifestyle and Global Housing segments, favorable analyst sentiment with 4 of 6 analysts raising estimates, attractive valuation metrics (P/B 2.34X below industry average), strong ROE of 20.4% and ROIC of 13.4%, Zacks Rank #2 (Buy) rating, and 16.2% upside potential from analyst price targets.

Mentioned as a better-ranked stock in the Finance sector with Zacks Rank #1 (Strong Buy), but no direct connection to the Marsh Archer announcement. Included only for comparative investment analysis purposes.

Mentioned as peer comparison with slight 0.1% decline over past month, trading at multiple higher than industry average. No specific operational details provided.

Mentioned only as a comparable company trading at a discount to industry average valuation; no specific analysis or performance data provided.

Expected 2026 sales growth of 8.5%, carries Zacks Rank #2 (Buy), meets screening criteria for cash flow, operating margins, and estimate revisions

AIZ carries a Zacks Rank #2 (Buy) with expected 11.5% year-over-year earnings growth. The company has beaten earnings estimates in each of the last four quarters (average 17.7% surprise) and received two upward estimate revisions against none in the past month.

Zacks Rank #2 (Buy) with 11.5% projected earnings growth, multiple upward estimate revisions (5 upward, 0 downward in past month), and consistent earnings beats (17.7% average surprise).

Carries Zacks Rank #2 (Buy) with consistent earnings surprises averaging 17.74% and strong projected earnings growth of 11.5% (2026) and 5.5% (2027). Stock gained 32% in the past year.

Solid financial performance with Connected Living division reporting ~14% revenue growth and ~21% EBITDA growth, analyst 'Strong Buy' view with average price target suggesting over 9% upside, low volatility with beta of 0.54